Possible involvement of an impaired baroreflex mechanism but not the renin-angiotensin system and vasopressin in the enhanced pressor responsiveness to physostigmine in spontaneously hypertensive rats

Koichiro Kawashima, Yuko Miwa, Kazuko Fujimoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

1. 1. Effects of physostigmine on heart rate, mean arterial pressure (MAP), plasma renin concentration (PRC) and vasopressin (AVP) release were investigated in spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats. 2. 2. Physostigmine (100 μg/kg, i.a.) produced a greater and prolonged hypertensive response in the SHR than in the WKY. 3. 3. Heart rate was increased by physostigmine in SHR rats while it was unchanged in the WKY. 4. 4. PRC was unchanged or even slightly decreased in these animals when MAP was increased by physostigmine. 5. 5. An AVP pressor antagonist did not attenuate the pressor and cardiac effects of physostigmine in these animals. 6. 6. These data indicate that an impaired baroreflex mechanism of a different mode of sympathetic neuronal activation by physostigmine through the central mechanism appears to be contributory, at least in part, to the enhanced pressor responsiveness in the SHR. 7. 7. The renin-angiotensin system and AVP do not appear to be involved in the enhanced pressor responsiveness to physostigmine in SHR rats.

Original languageEnglish
Pages (from-to)327-330
Number of pages4
JournalGeneral Pharmacology
Volume18
Issue number3
DOIs
Publication statusPublished - 1987

Fingerprint

Physostigmine
Baroreflex
Inbred SHR Rats
Renin-Angiotensin System
Vasopressins
Renin
Arterial Pressure
Heart Rate
Inbred WKY Rats

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{e47eb593ef3b4635b7330ce8eae518c4,
title = "Possible involvement of an impaired baroreflex mechanism but not the renin-angiotensin system and vasopressin in the enhanced pressor responsiveness to physostigmine in spontaneously hypertensive rats",
abstract = "1. 1. Effects of physostigmine on heart rate, mean arterial pressure (MAP), plasma renin concentration (PRC) and vasopressin (AVP) release were investigated in spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats. 2. 2. Physostigmine (100 μg/kg, i.a.) produced a greater and prolonged hypertensive response in the SHR than in the WKY. 3. 3. Heart rate was increased by physostigmine in SHR rats while it was unchanged in the WKY. 4. 4. PRC was unchanged or even slightly decreased in these animals when MAP was increased by physostigmine. 5. 5. An AVP pressor antagonist did not attenuate the pressor and cardiac effects of physostigmine in these animals. 6. 6. These data indicate that an impaired baroreflex mechanism of a different mode of sympathetic neuronal activation by physostigmine through the central mechanism appears to be contributory, at least in part, to the enhanced pressor responsiveness in the SHR. 7. 7. The renin-angiotensin system and AVP do not appear to be involved in the enhanced pressor responsiveness to physostigmine in SHR rats.",
author = "Koichiro Kawashima and Yuko Miwa and Kazuko Fujimoto",
year = "1987",
doi = "10.1016/0306-3623(87)90020-6",
language = "English",
volume = "18",
pages = "327--330",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Possible involvement of an impaired baroreflex mechanism but not the renin-angiotensin system and vasopressin in the enhanced pressor responsiveness to physostigmine in spontaneously hypertensive rats

AU - Kawashima, Koichiro

AU - Miwa, Yuko

AU - Fujimoto, Kazuko

PY - 1987

Y1 - 1987

N2 - 1. 1. Effects of physostigmine on heart rate, mean arterial pressure (MAP), plasma renin concentration (PRC) and vasopressin (AVP) release were investigated in spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats. 2. 2. Physostigmine (100 μg/kg, i.a.) produced a greater and prolonged hypertensive response in the SHR than in the WKY. 3. 3. Heart rate was increased by physostigmine in SHR rats while it was unchanged in the WKY. 4. 4. PRC was unchanged or even slightly decreased in these animals when MAP was increased by physostigmine. 5. 5. An AVP pressor antagonist did not attenuate the pressor and cardiac effects of physostigmine in these animals. 6. 6. These data indicate that an impaired baroreflex mechanism of a different mode of sympathetic neuronal activation by physostigmine through the central mechanism appears to be contributory, at least in part, to the enhanced pressor responsiveness in the SHR. 7. 7. The renin-angiotensin system and AVP do not appear to be involved in the enhanced pressor responsiveness to physostigmine in SHR rats.

AB - 1. 1. Effects of physostigmine on heart rate, mean arterial pressure (MAP), plasma renin concentration (PRC) and vasopressin (AVP) release were investigated in spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats. 2. 2. Physostigmine (100 μg/kg, i.a.) produced a greater and prolonged hypertensive response in the SHR than in the WKY. 3. 3. Heart rate was increased by physostigmine in SHR rats while it was unchanged in the WKY. 4. 4. PRC was unchanged or even slightly decreased in these animals when MAP was increased by physostigmine. 5. 5. An AVP pressor antagonist did not attenuate the pressor and cardiac effects of physostigmine in these animals. 6. 6. These data indicate that an impaired baroreflex mechanism of a different mode of sympathetic neuronal activation by physostigmine through the central mechanism appears to be contributory, at least in part, to the enhanced pressor responsiveness in the SHR. 7. 7. The renin-angiotensin system and AVP do not appear to be involved in the enhanced pressor responsiveness to physostigmine in SHR rats.

UR - http://www.scopus.com/inward/record.url?scp=0023154731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023154731&partnerID=8YFLogxK

U2 - 10.1016/0306-3623(87)90020-6

DO - 10.1016/0306-3623(87)90020-6

M3 - Article

C2 - 3552864

AN - SCOPUS:0023154731

VL - 18

SP - 327

EP - 330

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 3

ER -